松井佑梨世、中村知樹、松原孝夫、浅沼邦洋、松峯昭彦、須藤啓広	下腿遠位部悪性骨腫瘍に対する処理骨を用いた患肢温存術の治療成績	中部日本整形外科災害外科学会雑誌	55	489-490	2012
坂野真士、須藤啓広、長谷川正裕、廣瀬士朗、佐藤啓二、小林正明、水谷潤、大塚隆信、森敦幸、角田恒、清水克時、金治有彦、伊達秀樹、山田治基、星野裕信、松山幸弘、石黒直樹	整形外科術後静脈血栓塞栓症の発生における季節変動　東海地区における多施設調査	整形外科	63	601-604	2012
和田英夫、大内祐介、勝矢修嵩、登勉、吉田格之進、須藤啓広、山田典、中村真潮	整形外科術後の抗Xa剤投与における線溶亢進は出血の原因になり得る	心臓	44	877-878	2012
西村明展、中空繁登、須藤啓広、加藤公	外反母趾の重症度・有病率と危険因子の検討 第7回旧宮川村検診より	日本足の外科学会雑誌	33	29-32	2012
長谷川正裕、須藤啓広	【変形性膝関節症の保存療法】 変形性膝関節症の診断マーカー	Orthopaedics	25	1-6	2012
榎屋友幸、村木優一、岩本卓也、川瀬亮介、長谷川正裕、須藤啓広、内田淳正、奥田真弘	人工関節置換術後のフォンダパリヌクス投与患者における深部静脈血栓残存に影響する危険因子	薬学雑誌	132	683-687	2012
須藤啓広	【知っておきたい最新骨粗鬆症診療マニュアル】骨粗鬆症診断の進め方 診断基準、鑑別診断	Orthopaedics	25	51-56	2012
明田浩司、今西隆夫、小畑秀司、大石晃嗣、舛田浩、榊原紀彦、笠井裕一、内田淳正、須藤啓広	多血小板血漿を用いた椎間板修復治療の開発　椎間板性疼痛患者に対する臨床経験	Journal of Spine Research	3	685-689	2012
西村明展、加藤公、福田亜紀、藤澤幸三、内田淳正、須藤啓広	変形性足関節症に対する鏡視下足関節固定術の治療成績	中部日本整形外科災害外科学会雑誌	55	817-818	2012
今西隆夫、原隆久、池村重人、須藤啓広	90歳以上の超高齢者大腿骨近位部骨折の検討	整形外科	63	1227-1230	2012
西村明展、長谷川正裕、加藤公、須藤啓広	【人工関節とスポーツ】THA後のスポーツ活動 THA前後のスポーツ活動について 当院での現状	関節外科	31	1328-1333	2012
今西隆夫、明田浩司、長谷川正裕、榊原紀彦、笠井裕一、須藤啓広	脊椎手術患者の周術期における深部静脈血栓症の発症率と危険因子	Journal of Spine Research	3	1217-1221	2012

柿本拓也、辻井雅也、松峯昭彦、里中東彦、松原孝夫、須藤啓広	手関節部腫瘍切除後再建に血管柄付き骨移植術を用いた固定術を施行した2例	中部日本整形外科災害外科学会雑誌	55	903-904	2012
吉田格之進、長谷川正裕、若林弘樹、須藤啓広	短外旋筋群温存後方進入THA例の検討	東海関節	4	59-61	2012
長谷川正裕、須藤啓広	人工膝関節置換術の成績向上をめざして	東海関節	4	41-45	2012
吉田格之進、長谷川正裕、若林弘樹、須藤啓広	ナビゲーション　人工股関節置換術におけるCT-based navigation systemの有用性	日本人工関節学会誌	42	641-642	2012
松井佑梨世、長谷川正裕、渡上弘美、北畠智子、平井美希、吉田格之進、若林弘樹、須藤啓広	THA周術期　人工関節置換術前のエリスロポエチン製剤皮下注射時における痛みの検討	日本人工関節学会誌	42	509-510	2012
吉田格之進、長谷川正裕、若林弘樹、須藤啓広	THA画像評価　梨状筋の走行変化に関するMRI冠状断での評価	日本人工関節学会誌	42	463-464	2012
松井佑梨世、松峯昭彦、森本政司、竹上徳彦、吉川智朗、須藤啓広	骨悪性腫瘍との鑑別を要した橈骨遠位部骨クリプトコッカス症の1例	中部日本整形外科災害外科学会雑誌	55	1319-1320	2012
新美塁、河野稔文、服部朗子、西原淳、河野稔彦、須藤啓広	テリパラチド治療における年齢の影響	整形・災害外科	55	1685-1689	2012
宮腰尚久、山本智章、萩野浩、石井光一、大西五三男、加藤義治、斎藤充、須藤啓広、楊鴻生、遠藤直人、谷俊一	大腿骨頸部(近位部)骨折地域連携クリティカルパスの実態に関する全国調査	日本整形外科学会雑誌	86	913-920	2012
瀧川慎也、辻井雅也、植村剛、里中東彦、堀和一郎、須藤啓広	受傷後1ヵ月で観血的整復をした両側月状骨脱臼・月状骨周囲脱臼の1例	中部日本整形外科災害外科学会雑誌	55	389-390	2012
若林弘樹、長谷川正裕、吉田格之進、須藤啓広	モジュラー型メタル・オン・メタル人工股関節を用いた治療成績	整形外科	53	1044-1047	2012
里中東彦、辻井雅也、植村和司、堀和一郎、植村剛、須藤啓広	鎖骨遠位端骨折に対する手術成績	中部日本整形外科災害外科学会雑誌	55	167-168	2012
海野宏至、辻井雅也、植村剛、里中東彦、甲斐基一、須藤啓広	第1肋骨形態異常により生じた血管性胸郭出口症候群の1例	中部日本整形外科災害外科学会雑誌	55	155-156	2012
長谷川正裕、松井佑梨世、須藤啓広	人工関節置換術前のエリスロポエチン製剤皮下注射時における痛みの検討	Therapeutic Research	33	437-440	2012

下仮屋雄二、野間桂、池尻誠、西岡淳二、和田英夫、吉田格之進、長谷川正裕、須藤啓広、登勉	人工関節置換術後のフォンダパリヌクス投与患者における出血傾向と線溶系マーカーの関係	日本検査血液学会雑誌	13	41-48	2012
柿本拓也、西村明展、福田亜紀、加藤公、須藤啓広	鷲足部に遊離体を形成した女子サッカー部員の1例	整形外科	64	245-247	2013
新美塁、河野稔文、黒田健嗣、水野晴良、西原淳、河野稔彦、須藤啓広	骨形成作用を有する骨粗鬆症治療薬テリパラチドの治療成績	臨床整形外科	48	59-65	2013
Kamitani K, Michikawa T, Iwasawa S, Eto N, Tanaka T, Takebayashi T, Nishiwaki Y	Spinal Posture in the Sagittal Plane Is Associated With Future Dependence in Activities of Daily Living: A Community-Based Cohort Study of Older Adults in Japan.	J Gerontol A Biol Sci Med Sci			in press
西脇祐司、道川武紘	【骨・関節疾患の疫学研究の現状と今後】 介護予防と脊柱後彎姿勢	整形・災害外科	55	1651-1657	2012
Takiguchi N, Yoshida M, Taniguchi W, Hashizume H, Yamada H, Miyazaki N, Nishio N, Nakatsuka T	Distinct degree of radiculopathy at different levels of peripheral nerve injury.	Mol Pain	8	31	2012
Okada M, Minamide A, Yoshida M, Kawakami M, Enyo Y, Endo T	Observations in the diagnosis of cervical myelopathy in patients suffering from diabetes mellitus.	Spinal Cord	50	878-881	2012
Yamada H, Yoshida M, Hashizume H, Minamide A, Nakagawa Y, Kawai M, Iwasaki H, Tsutsui S	Efficacy of novel minimally invasive surgery using spinal microendoscope for treating extraforaminal stenosis at the lumbosacral junction.	J Spinal Disord Tech	25	268-276	2012
Enyo Y, Yamada H, Hoon Kim J, Yoshida M, Hutton WC	Microendoscopic Lateral Decompression for Lumbar Foraminal Stenosis: A Biomechanical Study.	J Spinal Disord Tech			in press
Terabe Y, Harada A, Tokuda H, Okuizumi H, Nagaya M, Shimokata H	Vitamin D Deficiency in Elderly Women in Nursing Homes: Investigation with Consideration of Decreased Activation Function from the Kidneys.	J Am Geriatr Soc	60	251-255	2012
Kozakai R, Ando F, Kim HY, Rantanen T, Shimokata H	Regular exercise history as a predictor of exercise in community-dwelling older Japanese people.	J Phys Fitness Sports Med	1	1-8	2012

Matsui Y, Takemura M, Harada A, Ando F, Shimokata H	Divergent significance of bone mineral density changes in aging depending on sites and sex revealed through separate analyses of bone mineral content and area.	J Osteoporos	2012	1-6	2012
Hida T, Ishiguro N, Shimokata H, Sakai Y, Matsui Y, Takemura M, Terabe Y, Harada A	High prevalence of sarcopenia and reduced leg muscle mass in Japanese patients immediately after a hip fracture.	Geriat Geront Int	13	413-420	2013
下方浩史、安藤富士子	日常生活機能と骨格筋量、筋力との関連	日老会誌	49	195-198	2012
下方浩史、安藤富士子	疫学研究からのサルコペニアとそのリスク－特に栄養との関連	日老会誌	49	721-725	2012
安藤富士子、今井具子、加藤友紀、大塚礼、松井康素、竹村真里枝、下方浩史	血清カロテノイドと2年後の骨粗鬆症／骨量減少発症リスクに及ぼす影響	日本未病システム学会雑誌	18	89-92	2012
松井康素、竹村真里枝、原田敦、安藤富士子、下方浩史	地域在住中高齢者の膝関節変形と膝伸展筋力との関連	Osteoporosis Jpn			in press
下方浩史、安藤富士子	検査基準値の考え方－医学における正常と異常－	日老会誌			in press
幸篤武、安藤富士子、下方浩史	サルコペニア、虚弱の疫学－日本人データから	Bone Joint Nerve			in press
下方浩史，安藤富士子	健康長寿社会を築く長期縦断疫学研究	日本未病システム学会雑誌			in press
大塚礼、下方浩史、安藤富士子	高齢者の栄養に関する疫学研究	Geriatric Medicine			in press

Ⅳ. 研究成果の刊行物・別刷

XI 大規模臨床試験の概要・住民コホート研究の概要

LOCOMOスタディ

The longitudinal cohorts of motor system organ (LOCOMO) study

吉村典子[1] 中村耕三[2] 阿久根徹[3] 藤原佐枝子[4]
清水容子[5] 吉田英世[5] 大森豪[6] 須藤啓広[7]
西脇祐司[8] 吉田宗人[9] 下方浩史[10]

Key words：コホート，要介護，運動器障害，発生率，有病率

はじめに

介護予防対策の推進により健康寿命を延伸し，膝痛・腰痛・骨折などの運動器障害による要介護高齢者を低減させるためには，運動器障害とその主要原因疾患(変形性膝関節症(KOA)，変形性腰椎症(LS)，骨粗鬆症(OP))に関する日本人の疫学エビデンスを構築し，危険因子を解明することが必須であるが，それらは皆無に近かった．

そこで厚生労働科学研究費補助金(長寿科学総合研究事業)により，平成20年度に'膝痛・腰痛・骨折に関する高齢者介護予防のための地域代表性を有する大規模住民コホート追跡研究'班(主任研究者 吉村典子)が立ち上がることとなった．研究班では，膝痛，腰痛，ならびにその原因疾患であるKOA，LS，OPによる大腿骨頸部骨折，脊椎椎体骨折などの発生率，有病率の推移，予後などの疫学指標を確立し，危険因子を同定すること，更に日常生活活動度(ADL)，生活の質(QOL)や要介護度との関係を検証しエビデンスを解明することを主目的としている．

この目的を達成するために，研究班では，まず地域代表性をもち骨関節疾患を予防目的として運営されてきた全国の9コホート，すなわち，東京1，東京2，和歌山，広島，三重，新潟，秋田，群馬，愛知のうち，8コホートの情報を統合した大規模統合コホートの構築を行い，愛知コホートを検証コホートとし，この一連の研究を，the longitudinal cohorts of motor system organ (LOCOMO)スタディと名づけた．

本稿では，LOCOMOスタディの概要とそれによる成果について報告する[1]．

[1]Noriko Yoshimura: Department of Joint Disease Research, 22nd Century Medical and Research Center, The University of Tokyo 東京大学医学部附属病院 22世紀医療センター 関節疾患総合研究講座 [2]Kozo Nakamura: Rehabilitation Service Bureau, National Rehabilitation Center for Persons with Disabilities 国立障害者リハビリテーションセンター研究所 自立支援局 [3]Toru Akune: Department of Clinical Motor System Medicine, 22nd Century Medical and Research Center, The University of Tokyo 東京大学医学部附属病院 22世紀医療センター 臨床運動器医学講座 [4]Saeko Fujiwara: Hiroshima Atomic Bomb Casualty Council 広島原爆障害対策協議会 [5]Yoko Shimizu, Hideyo Yoshida: Tokyo Metropolitan Institute of Gerontology 東京都健康長寿医療センター [6]Go Omori: Center for Transdisciplinary Research, Institute for Research Promotion, Niigata University 新潟大学超域研究機構 [7]Akihiro Sudo: Department of Orthopaedic Surgery, Mie University Graduate School of Medicine 三重大学医学部整形外科学 [8]Yuji Nishiwaki: Department of Environmental and Occupational Health, Faculty of Medicine, Toho University 東邦大学医学部 衛生学 [9]Munehito Yoshida: Department of Orthopedic Surgery, Wakayama Medical University 和歌山県立医科大学医学部 整形外科学 [10]Hiroshi Shimokata: Department of Epidemiology, National Center for Geriatrics and Gerontology 国立長寿医療研究センター 予防開発部

表1 大規模統合コホートの地域・性別参加者数

地域コホート	総 数	男 性	女 性
東京①	1,350	465	885
和歌山(山村)	864	319	545
和歌山(漁村)	826	277	549
広島	2,613	794	1,819
三重	1,175	423	752
新潟	1,474	628	846
東京②	1,453	59	1,394
秋田	852	366	486
群馬	1,412	628	784
総計	12,019	3,959	8,060

1 LOCOMOスタディの構築

LOCOMOスタディは，我が国において骨関節疾患予防を目的として行われてきた代表的な8コホート，すなわち東京1，東京2，和歌山，広島，三重，新潟，秋田，群馬の情報統合データベースと，統合コホートで得られた結果の妥当性を検証するため検証コホート(愛知)からなる．検証コホートでは，大規模統合コホートと同様のベースライン項目の解析，および同内容の追跡調査を行い，大規模統合コホートの結果の妥当性を確認することとした．

LOCOMOスタディで，ベースラインデータ共通項目として統合しえた項目は以下のとおりである：

(1) ID，性別，アンケート実施年月日
(2) ベースライン時年齢
(3) 身長，体重，体格指数(body mass index (BMI)，kg/m^2)
(4) 飲酒，喫煙
(5) 膝痛，腰痛の有無
(6) 転倒の有無
(7) 骨折の既往
(8) 骨密度
(9) 閉経年齢
(10) 膝X線結果
(11) 腰椎X線結果
(12) 脊椎圧迫骨折(X線)結果

更にこれらの追跡を行い，要介護認定の有無および要介護認定の時期を特定し，要介護移行率を推定した．

2 LOCOMOスタディ参加者の背景要因

LOCOMOスタディ統合コホートを形成する8コホートにおいて，無記名化データの抽出，統合を行い，12,019人(男性3,959人，女性8,060人)からなる大規模統合コホートデータベースの構築に成功した．**表1**にそのコホート別参加者数を，**表2**に性・年齢別分布を示す．参加者数として最も多いのは70歳代(41.9%)であり，続いて60歳代(26.4%)，80歳代(17.6%)であった．

表3に統合対象者の特徴を示す．参加者の平均年齢は男性70.0歳，女性71.0歳となり，女性に高かった($p<0.001$)．また平均身長，平均体重はいずれも男性の方が高かったが，体格指数であるBMIは男性22.8kg/m^2，女性23.0kg/m^{2}となり，女性に有意に高かった($p<0.01$)．喫煙率，飲酒率はいずれも男性に高かった($p<0.001$)．

3 要介護移行率の推定と危険因子

LOCOMOスタディ統合コホート12,019人のデータベースから，要介護認定の有無および要介護認定の時期を特定できた5コホート6地

表2 大規模統合コホートの性・年齢別参加者数

年齢（歳）	総数（%）	男性（%）	女性（%）
−19	1(0.01)	1(0.03)	0(0.00)
20−29	35(0.3)	16(0.4)	19(0.2)
30−39	89(0.7)	32(0.8)	57(0.7)
40−49	483(4.0)	183(4.6)	300(3.7)
50−59	963(8.0)	320(8.1)	643(8.0)
60−69	3,170(26.4)	1,161(29.3)	2,009(24.9)
70−79	5,041(41.9)	1,573(39.7)	3,468(43.0)
80−89	2,111(17.6)	627(15.8)	1,484(18.4)
90−	126(1.1)	46(1.2)	80(1.0)
総計	12,019(100.0)	3,959(100.0)	8,060(100.0)

表3 大規模統合コホート参加者の身体特性

項目	男性	女性
年齢（歳）	70.0(10.6)	71.0(10.3)
身長（cm）	161.1(6.8)	148.5(6.4)
体重（kg）	59.3(9.5)	50.8(8.6)
BMI（kg/m^2）	22.8(3.0)	23.0(3.5)
喫煙［%］	34.0	4.8
飲酒［%］	52.4	21.1

平均値（標準偏差）.

域（和歌山（山村，漁村），秋田，群馬，三重，東京2）の65歳以上の地域住民4,987人（平均年齢76.3歳）を対象とした.

この対象者から，65歳以上の要介護移行率を推定すると，総数で4.52/100人年（男性4.05/100人年，女性4.76/100人年）であることがわかった．これを性・年代別に**図1**に示す.

この要介護移行率を平成22年度国勢調査による性・年齢別人口比率を用いて計算すると，年間141万人（男性49万人，女性92万人）が要介護に移行することがわかった.

次に，要介護移行の危険因子をCoxの比例ハザードモデルを用いて推定した．目的変数を要介護移行とし，性，年齢，体格，地域を説明変数としてモデルに入れて検討したところ，年齢が高いほど要介護移行へのリスクは高く（+1歳，hazard ratio 1.13，95％信頼区間1.11−1.15，$p<0.001$），地域差が存在することがわかった（vs 東京2，和歌山山村0.49，0.34−0.7，$p<0.001$；和歌山漁村0.46，0.29−0.74，$p=0.002$；秋田，群馬，三重は東京2と有意な地域差なし）．性差，体格については有意な差異は認められなかった.

おわりに

膝痛・腰痛・骨折は高齢者のADLやQOLを著しく低下させ，ひいては要介護状態に陥る原因となるため，LOCOMOスタディではこれら運動器疾患の予防による高齢者の要介護予防を最終目的としている.

厚生労働省研究班では，初年度，2年目の2年間で高齢者要介護予防のための地域代表性を有する住民コホートの共通のデータを統合し，大規模コホートデータベースを構築することができた．このデータベース構築には，全国8地域の住民コホートが参加しており，まさに全国規模の調査結果といってよい．更に参加者総数約12,000人，検証コホートを含めると14,500人



図1 要介護移行率

の男女が参加している本コホートは世界的にみても類をみない規模である．今回はLOCOMOスタディの成果の一つとして，既に要介護情報などの取得に成功した和歌山県(山村，漁村)，秋田県，群馬県，三重県，東京2在住の65歳以上の住民から推定した要介護移行率と年齢，地域差の影響について紹介した．今後，ベースライン結果と追跡調査の結果をリンクし，オールジャパンデータでの膝痛，腰痛，骨折の発生率やそれに影響を及ぼす要因，また要介護移行率の更なる危険因子の解明を行い，要介護状態の一次，二次，三次予防に質の高いエビデンスを供給し，地域在住高齢者のADL，QOLの向上に寄与できるように努力したい．

文 献

1) 吉村典子：厚生労働科学研究費補助金(長寿科学総合研究事業)平成23年度総括報告書．

Osteoarthritis and Cartilage 20 (2012) 1217–1226

Osteoarthritis and Cartilage

OARSI OSTEOARTHRITIS RESEARCH SOCIETY INTERNATIONAL

Accumulation of metabolic risk factors such as overweight, hypertension, dyslipidaemia, and impaired glucose tolerance raises the risk of occurrence and progression of knee osteoarthritis: a 3-year follow-up of the ROAD study

N. Yoshimura †*, S. Muraki ‡, H. Oka †, S. Tanaka §, H. Kawaguchi §, K. Nakamura ||, T. Akune ‡

† *Department of Joint Disease Research, 22nd Century Medical and Research Center, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan*
‡ *Department of Clinical Motor System Medicine, 22nd Century Medical and Research Center, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan*
§ *Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan*
|| *Rehabilitation Services Bureau, National Rehabilitation Center for Persons with Disabilities, 1, Namiki 4-chome, Tokorozawa City, Saitama Prefecture 359-8555, Japan*

ARTICLE INFO

Article history:
Received 15 March 2012
Accepted 21 June 2012

Keywords:
Knee osteoarthritis
Incidence
Progression
Metabolic syndrome
Population-based cohort study

SUMMARY

Objective: To clarify the association between the occurrence and progression of knee osteoarthritis (KOA) with components of metabolic syndrome (MS), including overweight (OW), hypertension (HT), dyslipidaemia (DL), and impaired glucose tolerance (IGT), in a general population.
Design: From the large-scale population-based cohort study entitled Research on Osteoarthritis/Osteoporosis Against Disability (ROAD) initiated in 2005, 1,690 participants (596 men, 1,094 women) residing in mountainous and coastal areas were enrolled. Of these, 1,384 individuals (81.9%; 466 men, 918 women) completed the second survey, including knee radiography, 3 years later. KOA was defined as Kellgren–Lawrence (KL) grade ≥ 2 using paired X-ray films. Based on changes in KL grades between the baseline and second surveys, cumulative incidence and progression of KOA were determined. OW, HT, DL, and IGT at baseline were assessed using standard criteria.
Results: The cumulative incidence of KOA among 1,384 completers over 3 years was 3.3%/year, and progression in KL grades for either knee, 8.0%/year. Logistic regression analyses after adjusting for potential risk factors revealed that the odds ratio (OR) for the occurrence of KOA significantly increased according to the number of MS components present (OR vs no component: one component, 2.33; two components, 2.82; ≥three components, 9.83). Similarly, progression of KOA significantly increased according to the number of MS components present (OR vs no component: one component, 1.38; two components, 2.29; ≥three components: 2.80).
Conclusion: Accumulation of MS components is significantly related to both occurrence and progression of KOA. MS prevention may be useful in reducing future KOA risk.

Introduction

Osteoarthritis (OA), which causes cartilage and disc degeneration and osteophyte formation at joints in the limbs and spine, is a major public health problem in the elderly and affects activities of daily living and quality of life, leading to increased morbidity and mortality[1–3]. According to the recent National Livelihood Survey by the Ministry of Health, Labour and Welfare in Japan, OA is ranked fourth among diseases that cause disabilities requiring support and long-term care[4]. The National Livelihood Survey also shows that cardiovascular disease (CVD) is ranked first in causing disabilities in the elderly[4]. Most CVD patients have multiple risk factors[5]. The presence of these risk factors in a specific combination, entitled metabolic syndrome (MS), is a multiplex risk factor that predisposes affected individuals to CVD morbidity and mortality. MS is generally considered a combination of being overweight (OW) and having hypertension (HT), dyslipidaemia (DL), and impaired glucose tolerance (IGT)[6].

Knee OA (KOA) and MS share age and obesity as risk factors[1,7–12]. Numerous investigators have associated OA with

* Address correspondence and reprint requests to: N. Yoshimura, Department of Joint Disease Research, 22nd Century Medical and Research Center, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. Tel: 81-3-5800-9178; Fax: 81-3-5800-9179.
E-mail address: YOSHIMURAN-ORT@h.u-tokyo.ac.jp (N. Yoshimura).

1063-4584/$ – see front matter © 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
http://dx.doi.org/10.1016/j.joca.2012.06.006

various MS components. Lawrence first reported that diastolic blood pressure (BP) was associated with KOA in women[13]. Kellgren reported that hand OA was significantly associated with above-average serum cholesterol levels in women[14]. Cimmino *et al.* observed significantly higher plasma glucose levels in women with OA than in those without[15]. Contradictory findings regarding the association of such metabolic factors with OA have been reported[16–19]. Hart *et al.* found that metabolic factors such as blood glucose, hypercholesterolaemia, and even treated HT were associated with KOA development[20]. A few population-based studies have demonstrated a dose–response relationship between risk factor accumulation for MS and KOA; we have previously reported that KOA presence was significantly associated with increase in the number of MS components[21]. However, to our knowledge, no study has clarified the associations between KOA occurrence or progression and MS component accumulation, using a prospective cohort of general inhabitants.

This study evaluated the incidence and progression of radiographic KOA and its associations with individual and cumulative MS components (OW, HT, DL, and IGT) among men and women using the large-scale, population-based cohort from the Research on Osteoarthritis/Osteoporosis Against Disability (ROAD) study.

Method

Participants

This study involved the cohorts established in 2005 for the ROAD study. Details of the cohort profile have been reported elsewhere[22,23] and are only briefly described here. In 2005–2007, we created a baseline database including clinical information for 3,040 residents of Japan (men, 1,061; women, 1,979). The subjects were recruited from resident registration listings in three communities with different characteristics: 1,350 individuals (men, 465; women, 885) from an urban region in Itabashi, Tokyo; 864 individuals (men, 319; women, 545) from a mountainous region in Hidakagawa, Wakayama; and 826 individuals (men, 277; women, 549) from a coastal region in Taiji, Wakayama. In 2008–2010, we attempted to locate and follow-up all 3,040 subjects. They were invited for the second survey of the ROAD study, a 3-year follow-up examination identical to the baseline examinations.

For the current study, we enrolled all 1,690 subjects (men, 596; women, 1,094) resided in the mountainous and coastal areas, where blood examination had been performed on all participants at baseline. All participants provided written informed consent, and the study was conducted with approval from the ethics committees of the University of Tokyo.

Baseline examination procedures

At the baseline examination, participants completed an interviewer-administered questionnaire of 400 items, including lifestyle information such as primary occupation; smoking habits (0: ex- or non-smoker, 1: current smoker); alcohol consumption (0: ex- or non-drinker, 1: current drinker); physical activity, including bicycling every day over the past 12 months (0: no, 1: yes); regular exercise (0: no, 1: yes); and medical history, including history of knee injuries (0: no, 1: yes). The participants were asked whether they took prescription medication daily or nearly every day (0: no, 1: yes). If they did not know what their medications were prescribed for, they were asked to bring their medications to the medical doctor (NY).

Anthropometric measurements included height, weight, and body mass index [BMI: weight (kg)/height^2 (m^2)]. Systolic and diastolic BP was measured by an experienced public health nurse using a mercury sphygmomanometer. Medical information, including information on knee joints, was collected by experienced orthopaedic surgeons (SM and HO). All participants underwent radiographic examination of both knees using an anterior–posterior view with weight-bearing and foot-map positioning.

All blood samples were obtained between 09:00 and 15:00. Haemoglobin A1c (HbA1c), blood sugar, high-density lipoprotein cholesterol (HDL-cho), total cholesterol, and triglyceride (TG) levels were measured. All analyses were performed at the same laboratory within 24 h of extraction (Osaka Kessei Research Laboratories, Inc., Osaka, Japan).

In this study, definitions of MS components were based on criteria defined by the Examination Committee of Criteria for Metabolic Syndrome in Japan[24] and the Japan Society for the Study of Obesity[25]. However, because not all blood samples were obtained under fasting conditions, we used indices from the National Health and Nutrition Survey in Japan adopted as MS criteria in this national screening study due to the difficulty of collecting samples under fasting conditions[26]. The following definitions were used for MS components: OW, BMI $\geq$ 25 kg/m^2; HT, systolic BP $\geq$ 130 mm Hg and/or diastolic BP $\geq$ 85 mm Hg; DL, serum HDL-cho level $<$ 40 mg/dL; and IGT, serum HbA1c level $\geq$ 5.5%. Furthermore, subjects being treated with medication for HT, DL, or diabetes mellitus were regarded as having HT, DL, or IGT, respectively.

Three-year follow-up and definition of KOA occurrence and progression

In 2008–2010, the 1,690 subjects were invited to attend the second survey of the ROAD study, a 3-year follow-up consisting of examinations identical to those at baseline. Knee radiographs were read by a single experienced orthopaedist (SM) without knowledge of participants' clinical status and were categorized using the Kellgren–Lawrence (KL) grading scale[27]. When there were differences in the KL grades between the two knees, the higher KL grade was assigned to the participant. A subject with KL $\geq$ 2 was defined as having radiographic KOA. A new KOA case was identified if both knees had a KL grade $<$ 2 at baseline and if at least one knee developed a KL of $\geq$2 during follow-up. KOA progression was defined as the KL grade for either knee being higher during follow-up than at baseline.

Statistical analysis

All statistical analyses were performed using STATA statistical software (STATA Corp., College Station, TX, USA). Differences in proportions were compared using the chi-square test. Differences in continuous variables were tested for significance using analysis of variance for multiple groups or Scheffe's least significant difference test for pairs of groups. All P values and 95% confidence intervals (CI) are two-sided.

To clarify associations between KOA occurrence or progression and MS risk factors, we performed three types of multivariate logistic regression analysis. Model 1 was performed using KOA occurrence or progression (over 3 years, 1: yes, 0: no) as the objective variable. Each risk factor for MS, that is, continuous variables such as BMI, systolic BP, diastolic BP, and serum HDL-cho and HbA1c levels, and categorical variables such as OW (1: presence, 0: absence), HT (1: presence, 0: absence), DL (1: presence, 0: absence), and IGT (1: presence, 0: absence) were considered as an individual explanatory variable after adjusting for age and gender. Model 2 was performed using the same objective variable and individual explanatory factor for MS as in Model 1, after adjustment for age, gender, regional differences, smoking, alcohol

consumption, bicycling, regular exercise, and history of knee injuries, all of which had been found to be significantly associated with KOA presence in a previous study using the same population[17]. Model 3 was obtained by multivariate logistic regression analysis using the same objective variable and the same adjustment factors as in Model 2; furthermore, other MS components were included in the mutual adjustment model. For example, when BMI was selected as an objective factor, Model 3 was obtained by multivariate logistic regression after adjustment for age, gender, regional differences, smoking, alcohol consumption, bicycling, regular exercise, history of knee injuries, systolic BP, and serum HDL-cho and HBA1c levels. Similarly, when OW was selected as an objective factor, Model 3 was obtained by multivariate logistic regression after adjustment for age, gender, regional differences, smoking, alcohol consumption, bicycling, regular exercise, history of knee injuries, HT, DL, and IGT. Because systolic and diastolic BP was moderately correlated ($r = 0.5643$, $P < 0.001$), only values of systolic BP were used as representative of BP in Model 3.

To further evaluate associations between the number of MS components and KOA occurrence and progression, we used two multivariate logistic regression models. In Model 4, we used KOA occurrence or KL grade progression as the objective variable and the number of MS components present (OW, HT, DL, and IGT) as the explanatory variable, after adjusting for age and gender. In Model 5, we used KOA occurrence or progression as the objective variable and the number of MS components present as the explanatory variable, after adjusting for age, gender, regional differences, smoking, alcohol consumption, bicycling, regular exercise, and history of knee injuries.

Results

Eligible participants

Of the 1,690 baseline survey participants, 251 (14.9%; men, 104; women, 147) dropped out of the follow-up study. The reasons for the drop-outs are shown in Fig. 1. In this study, we used the data for the remaining 1,384 subjects (81.9%; men, 466; women, 918) who completed all examinations in both baseline and follow-up surveys.

Table I shows baseline characteristics of the 1,384 participants and mean values for BMI, systolic and diastolic BP, and serum HDL-cho and HbA1c levels, classified by gender. Men had significantly higher BMI, higher systolic and diastolic BP, and lower serum HDL-cho levels than women. However, serum HbA1c levels did not show



Fig. 1. Flow of participants in the baseline and second surveys.

Table I
Baseline characteristics of subjects who participated in both the first and second surveys

	Total	Men	Women	*P* (men vs women)
Number of subjects classified by age-strata (%)				
≤39 (year)	39 (2.8)	10 (2.1)	29 (3.2)	0.23
40–49	135 (9.8)	40 (8.6)	95 (10.3)	
50–59	298 (21.5)	99 (21.2)	199 (21.7)	
60–69	413 (29.8)	131 (28.1)	282 (30.7)	
70–79	404 (29.2)	155 (33.3)	249 (27.1)	
≥80	95 (6.9)	31 (6.7)	64 (7.0)	
Total	1384 (100.0)	466 (100.0)	918 (100.0)	
Means (standard deviations) of selected characteristics				
Age (year)	63.9 (11.8)	64.9 (11.6)	63.4 (11.9)	0.0246*
Height (cm)	155.6 (9.0)	164.0 (7.0)	151.3 (6.7)	<0.001***
Weight (kg)	56.0 (10.7)	62.1 (10.7)	52.5 (8.7)	<0.001***
Prevalence of selected characteristics, %				
Residing in a coastal area	54.1	51.9	55.2	0.245
Current smoking habit (more than once a month)	12.3	29.4	3.5	<0.001***
Current alcohol consumption (more than once a month)	40.6	68.2	26.6	<0.001***
Bicycling every day in the past 12 months	55.5	55.2	55.7	0.859
Regular exercise, i.e., football, tennis, baseball, or golf, after graduation from school (%)	15.3	36.1	4.7	<0.001***
Past injury of either knee (%)	2.5	1.9	2.8	0.313
Medication for components of MS, %				
Medication for HT	29.8	27.5	31.1	0.169
Medication for DL	7.2	3.4	9.2	<0.001***
Medication for diabetes mellitus, including insulin injection	5.6	7.3	4.8	0.056
Mean values (standard deviations) for components of MS				
BMI (kg/m^2)	23.1 (3.4)	23.4 (3.2)	22.9 (3.4)	0.0089
Systolic BP (mm Hg)	134.1 (20.4)	136.6 (18.3)	132.9 (21.4)	0.0015**
Diastolic BP (mm Hg)	74.2 (11.4)	77.0 (11.5)	72.8 (11.0)	<0.0001***
Serum levels of HDL-cho (mg/dL)	61.2 (15.9)	55.8 (16.1)	64.0 (15.0)	<0.0001***
Serum levels of HbA1c (%)	5.19 (0.73)	5.23 (0.85)	5.17 (0.67)	0.1900
Prevalence of components of MS, %				
OW	25.7	28.1	24.4	0.135
HT	67.2	72.7	64.4	0.002**
DL	13.0	15.2	11.9	0.079
IGT	21.1	24.7	19.3	0.020*

*$P < 0.05$, **$P < 0.01$, ***$P < 0.001$.

significant gender-based differences. In the total population, the MS component with the highest prevalence was HT, followed by OW, IGT, and DL. The prevalences of HT and IGT were significantly higher in men than in women.

KOA occurrence and progression and MS components

Baseline KOA prevalence in the 1,384 individuals was 46.8% (men, 37.3%; women, 51.6%). After exclusion of subjects having KOA (KL grade ≥ 2 in at least one knee) at baseline, the cumulative KOA incidence during the 3-year follow-up was estimated using a population-at-risk of 728 individuals (men, 290; women, 438) without

KOA in either knee at baseline. Among these subjects, 71 new KOA cases (men, 18; women, 53) were detected, with a cumulative incidence of 3.3%/year (men, 2.1%/year; women, 4.0%/year). After excluding subjects with KL grade = 4 for at least one knee at baseline, the progression rate over the 3-year follow-up was estimated using the population-at-risk of 1,296 individuals (men, 445; women, 851). Among these, 311 individuals (men, 86; women, 225) had a higher KL grade for one or both knees at follow-up than at baseline. The progression proportion of the KL grade for either knee over the 3-year period was 24.0% (8.0%/year; men, 6.4%/year; women, 8.8%/year) in the overall population-at-risk.

Table II shows cumulative KOA incidence and progression, classified by age groups of ≤39, 40–49, 50–59, 60–69, 70–79, and ≥80 years, which significantly increased with age. BMI, systolic BP, and HbA1c levels at baseline were significantly higher and HDL-cho levels significantly lower in subjects with KOA than in those without KOA. Similar to KOA, BMI, systolic BP, and HbA1c levels were significantly higher and HDL-cho levels significantly lower in subjects with KL grade progression than in those without. This tendency was much more pronounced in women than in men.

Table III shows multivariate logistic regression analysis results for KOA occurrence vs values for each MS component, including BMI, systolic BP, diastolic BP, and serum HDL-cho and HbA1c levels measured at baseline (Table III). Model 2 showed that BMI, systolic BP, and serum HDL-cho levels were significantly associated with KOA occurrence after adjustment for various risk factors. However, Model 3, incorporating mutual adjustment for each MS component, indicated that only BMI was significantly associated with KOA occurrence. The three types of multivariate logistic regression analyses using KOA progression as the objective factor showed similar results as for KOA occurrence described above.

Table IV shows associations between KOA occurrence and MS risk factors. Both Models 1 and 2 revealed that OW, HT, and IGT were significantly associated with KOA. Analysis using OW, HT, DL, and IGT as explanatory variables with mutual adjustment (Model 3) indicated that HT and IGT were significantly associated with KOA. Table IV also shows associations between KOA progression and MS risk factors, indicating that OW and HT were significantly associated with KOA progression. Although IGT was significantly associated with KOA progression after adjustment for age and gender, the effect diminished after adjustment for various other risk factors.

KOA occurrence and progression and the number of MS components

Figure 2 shows the cumulative KOA incidence (%/year) classified by the number of MS components present. In the total population, the cumulative incidence classified by the number of MS

Table II
Mean values (standard deviations) for components of MS vs occurrence and progression of KOA

	Total			Men			Women		
	KOA (−)	KOA (+)	*P*	KOA (−)	KOA (+)	*P*	KOA (−)	KOA (+)	*P*
	(*n* = 657)	(*n* = 71)		(*n* = 272)	(*n* = 18)		(*n* = 385)	(*n* = 53)	
Occurrence of KOA									
Number of subjects classified by age-strata (cumulative incidence, %/year)									
≤39 (year)	38	0 (0.0)	<0.001	10	0 (0.0)	0.009	28	0 (0.0)	<0.001
40–49	118	1 (0.3)		36	0 (0.0)		82	1 (0.4)	
50–59	201	15 (2.3)		77	0 (0.0)		124	15 (3.6)	
60–69	177	27 (4.4)		76	11 (4.2)		101	16 (4.6)	
70–79	108	23 (5.9)		62	6 (2.9)		46	17 (9.0)	
≥80	15	5 (8.3)		11	1 (2.8)		4	4 (16.7)	
Mean values (standard deviations) for age and components of MS									
Age (year)	58.2 (11.8)	67.3 (8.2)	<0.0001	61.0 (11.8)	70.0 (6.1)	0.0021	56.4 (11.4)	66.4 (8.7)	<0.0001
BMI (kg/m^2)	22.4 (3.2)	23.6 (2.9)	0.0035	23.2 (3.2)	24.2 (3.1)	0.1709	21.9 (3.1)	23.4 (2.8)	0.0012
Systolic BP (mm Hg)	129.6 (19.4)	138.2 (19.1)	0.0005	133.4 (17.9)	143.4 (17.7)	0.0255	127.0 (20.0)	136.5 (19.4)	0.0014
Diastolic BP (mm Hg)	74.3 (11.2)	74 (11.0)	0.8599	77.5 (11.8)	76.7 (10.7)	0.7907	72.0 (10.2)	73.2 (11.0)	0.4544
Serum levels of HDL-cho (mg/dL)	63.4 (16.8)	59.2 (13.3)	0.0414	57.3 (16.3)	54.6 (15.7)	0.5017	67.7 (15.8)	60.8 (12.1)	0.0021
Serum levels of HbA1c (%)	5.11 (0.67)	5.32 (0.79)	0.0142	5.24 (0.87)	5.09 (0.75)	0.4644	5.01 (0.46)	5.39 (0.80)	<0.0001
	Total			Men			Women		
	Progression (−) (*n* = 985)	Progression (+) (*n* = 311)	*P*	Progression (−) (*n* = 359)	Progression (+) (*n* = 86)	*P*	Progression (−) (*n* = 626)	Progression (+) (*n* = 255)	*P*
Progression of KOA									
Number of subjects classified by age-strata (proportion of progression, %/year)									
≤39 (year)	37	2 (1.7)	<0.001***	9	1 (3.3)	<0.001***	28	1 (1.1)	<0.001***
40–49	128	7 (1.7)		38	2 (1.7)		90	5 (1.8)	
50–59	248	44 (5.0)		89	8 (2.8)		159	36 (6.2)	
60–69	292	105 (8.2)		101	26 (6.8)		191	79 (9.8)	
70–79	241	115 (10.8)		105	38 (8.9)		136	77 (12.1)	
≥80	39	38 (16.5)		17	11 (13.1)		22	27 (18.4)	
Mean values (standard deviations) for age and components of MS									
Age (year)	61.6 (11.9)	68.7 (9.3)	<0.0001***	63.3 (11.8)	70.0 (9.4)	<0.0001***	60.7 (11.9)	68.2 (9.3)	<0.0001***
BMI (kg/m^2)	22.7 (3.3)	23.6 (3.1)	<0.0001***	23.2 (3.2)	23.9 (3.1)	0.0643	22.4 (3.3)	23.5 (3.1)	<0.0001***
Systolic BP (mm Hg)	132.2 (20.0)	137.9 (19.3)	<0.0001***	135.4 (17.9)	138.6 (17.0)	0.1390	130.4 (20.9)	137.6 (20.1)	<0.0001***
Diastolic BP (mm Hg)	74.0 (11.2)	74.5 (11.8)	0.5517	77.1 (11.6)	76.3 (10.6)	0.5698	72.3 (10.5)	73.8 (12.2)	0.0792
Serum levels of HDL-cho (mg/dL)	62.3 (16.6)	59.0 (13.8)	0.0018**	56.7 (16.4)	53.5 (15.2)	0.0921	65.4 (15.8)	61.1 (12.6)	0.0003***
Serum levels of HbA1c (%)	5.15 (0.72)	5.27 (0.74)	0.0133*	5.20 (0.84)	5.30 (0.88)	0.3687	5.11 (0.64)	5.25 (0.68)	0.0069**

KOA(−), non-occurrence of KOA; KOA(+), occurrence of KOA; progression(−), no progression of the KL grade; progression(+), progression of the KL grade.
n, number of subjects.
*$P < 0.05$, **$P < 0.01$, ***$P < 0.001$.

Table III
ORs for occurrence and progression of KOA during the 3-year follow-up period vs BMI, systolic and diastolic BP, serum levels of HDL-cho, and HbA1c level

Explanatory variables	Reference	Model 1*			Model 2†			Model 3‡		
		Adjusted OR1	95% CI	*P*	Adjusted OR2	95% CI	*P*	Adjusted OR3	95% CI	*P*
Occurrence of KOA										
BMI (kg/m^2)	+1 kg/m^2	1.22	1.12–1.33	<0.001***	1.22	1.12–1.34	<0.001***	1.18	1.07–1.30	0.001**
Systolic BP (mm Hg)	+1 mm Hg	1.54	0.87–2.72	0.136	1.01	1.00–1.03	0.038*	1.01	1.00–1.03	0.188
Diastolic BP (mm Hg)	+1 mm Hg	1.51	0.71–3.19	0.282	1.01	0.99–1.04	0.373	–	–	–
Serum levels of HDL-cho (mg/dL)	+1 mg/dL	0.980	0.962–0.999	0.039*	0.980	0.960–0.999	0.039*	0.989	0.968–1.009	0.256
Serum levels of HbA1c (%)	+1%	1.29	0.92–1.81	0.136	1.34	0.96–1.88	0.089	1.07	0.73–1.56	0.743
Progression of KOA										
BMI (kg/m^2)	+1 kg/m^2	1.12	1.08–1.17	<0.001***	1.13	1.08–1.18	<0.001***	1.11	1.06–1.17	<0.001***
Systolic BP (mm Hg)	+1 mm Hg	1.47	1.10–1.97	0.010*	1.01	1.00–1.01	0.039*	1.00	1.00–1.01	0.352
Diastolic BP (mm Hg)	+1 mm Hg	1.33	0.92–1.91	0.124	1.01	1.00–1.025	0.057	–	–	–
Serum levels of HDL-cho (mg/dL)	+1 mg/dL	0.988	0.979–0.997	0.011*	0.987	0.978–0.997	0.008**	0.992	0.983–1.002	0.137
Serum levels of HbA1c (%)	+1 %	1.11	0.94–1.33	0.227	1.11	0.93–1.32	0.277	0.99	0.81–1.19	0.881

*$P < 0.05$, **$P < 0.01$, ***$P < 0.001$.

* Model 1 was obtained by a series of multivariate logistic regression analyses using the occurrence or progression of KOA (over 3 years, 1: yes, 0: no) as the objective variable and each individual explanatory variable (BMI, systolic BP, diastolic BP, serum HDL-cho, or HbA1c) after adjusting for age and gender.

† Model 2 was obtained by a series of multivariate logistic regression analyses using the occurrence or progression of KOA (over 3 years, 1: yes, 0: no) as the objective variable and each individual explanatory variable (BMI, systolic BP, diastolic BP, serum HDL-cho, or HbA1c) after adjusting for age, gender, region (0: coastal area, 1: mountainous area), smoking (0: ex- or non-smoker, 1: current smoker), alcohol consumption (0: ex- or non-drinker, 1: current drinker), bicycling every day (0: no, 1: yes), regular exercise (0: no, 1: yes), and past history of knee injuries (0: no, 1: yes).

‡ Model 3 was obtained by multivariate logistic regression analysis using the occurrence or progression of KOA (over 3 years, 1: yes, 0: no) as the objective variable and each individual explanatory variable (BMI, systolic BP, diastolic BP, serum HDL-cho, or HbA1c) after adjusting for age, gender, region (0: coastal area, 1: mountainous area), smoking (0: ex- or non-smoker, 1: current smoker), alcohol consumption (0: ex- or non-drinker, 1: current drinker), bicycling every day (0: no, 1: yes), regular exercise (0: no, 1: yes), and past history of knee injuries (0: no, 1: yes), and other potential risk factors such as BMI, systolic BP, serum levels of HDL-cho, and HbA1c levels, mutually.

components (0, 1, 2, or ≥3) was 1.0, 3.5, 3.4, and 8.7, respectively, which increased with the number of MS components (*P* for trend < 0.001). Figure 2(A) also shows the cumulative KOA incidence according to the number of MS components by gender. The cumulative incidence among individuals with one or more MS components was higher in women than in men.

Figure 2 also shows KL grade progression (%/year) for either knee classified by the number of MS components present. In the total population, KL grade progression classified by 0, 1, 2, or ≥3 MS components was 4.3, 7.6, 10.8, and 11.3, respectively, which significantly increased with the number of MS components (*P* for trend < 0.001). The progression among individuals with one or more MS components was higher in women than in men [Fig. 2(B)].

To further illustrate the effects of the number of MS components on KOA occurrence and progression, Fig. 3 presents the results of the multivariate logistic regression analysis models for KOA occurrence. Model 4 used KOA occurrence or KL grade progression as the objective variable and the number of MS components present (OW, HT, DL, and IGT) as the explanatory variable, adjusted

Table IV
ORs for occurrence and progression of KOA during the 3-year follow-up period vs risk factors for MS

Explanatory variables	Reference	Model 1*			Model 2†			Model 3‡		
		Adjusted OR1	95% CI	*P*	Adjusted OR2	95% CI	*P*	Adjusted OR3	95% CI	*P*
Occurrence of KOA										
Component of MS										
OW	Yes vs no	2.36	1.28–4.34	0.006**	2.46	1.32–4.59	0.005**	1.71	0.88–3.33	0.114
HT	Yes vs no	3.02	1.47–6.23	0.003**	3.27	1.57–6.80	0.002**	2.74	1.30–5.78	0.008**
DL	Yes vs no	1.34	0.65–2.73	0.425	1.55	0.75–3.23	0.240	1.20	0.55–2.59	0.646
IGT	Yes vs no	2.42	1.37–4.27	0.002**	2.47	1.38–4.41	0.002**	1.94	1.05–3.59	0.033*
Progression of KOA										
Component of MS										
OW	Yes vs no	1.76	1.30–2.38	<0.001***	1.87	1.37–2.55	<0.001***	1.66	1.21–2.29	0.002**
HT	Yes vs no	1.75	1.26–2.42	0.001**	1.75	1.26–2.43	0.001**	1.54	1.10–2.17	0.012*
DL	Yes vs no	1.18	0.81–1.71	0.400	1.36	0.93–2.01	0.117	1.26	0.85–1.87	0.248
IGT	Yes vs no	1.42	1.04–1.94	0.029*	1.35	0.98–1.87	0.068	1.18	0.84–1.64	0.336

*$P < 0.05$, **$P < 0.01$, ***$P < 0.001$.

Being OW was defined as BMI ≥ 25 kg/m^2, HT as systolic BP ≥ 130 mm Hg and/or diastolic BP ≥ 85 mm Hg, DL as serum HDL-cho level < 40 mg/dL, and IGT as serum HbA1c level ≥ 5.5%. Further, subjects being treated with medication for HT, DL, or IGT were regarded as having the respective disorder.

* Model 1 was obtained by a series of multivariate logistic regression analyses using the occurrence or progression of KOA (over 3 years, 1: yes, 0: no) as the objective variable and each individual explanatory variable (being OW, HT, DL, or IGT) after adjusting for age and gender.

† Model 2 was obtained by a series of multivariate logistic regression analyses using the occurrence or progression of KOA (over 3 years, 1: yes, 0: no) as the objective variable and each individual explanatory variable (being OW, HT, DL, and IGT) after adjusting for age, gender, region (0: coastal area, 1: mountainous area), smoking (0: ex- or non-smoker, 1: current smoker), alcohol consumption (0: ex- or non-drinker, 1: current drinker), bicycling every day (0: no, 1: yes), regular exercise (0: no, 1: yes), and past history of knee injuries (0: no, 1: yes).

‡ Model 3 was obtained by multivariate logistic regression analysis using the occurrence or progression of KOA (over 3 years, 1: yes, 0: no) as the objective variable and being OW, HT, DL, and IGT as explanatory variables, after adjusting for age, gender, region (0: coastal area, 1: mountainous area), smoking (0: ex- or non-smoker, 1: current smoker), alcohol consumption (0: ex- or non-drinker, 1: current drinker), bicycling every day (0: no, 1: yes), regular exercise (0: no, 1: yes), past history of knee injuries (0: no, 1: yes), and other components of MS, mutually.



Fig. 2. Cumulative incidence (%/year) of KOA (A) and progression of the KL grade of either knee (%/year) (B) classified by the number of components of MS, including OW, HT, DL, and IGT.

for age and gender. The odds ratio (OR) and 95% CI for KOA occurrence were found to significantly increase with the number of MS components present (OR, 95% CI vs no component: one component, 2.16, 0.90–5.20, $P = 0.085$; two components, 2.49, 0.95–6.55, $P = 0.063$; ≥three components, 8.38, 3.12–22.5, $P < 0.001$). Similarly, KOA progression significantly increased with the number of MS components present (OR, 95% CI vs no component: one component, 1.41, 0.94–2.12, $P = 0.097$; two components, 2.25, 1.47–3.46, $P < 0.001$; ≥three components: 2.59, 1.57–4.27, $P < 0.001$).

Logistic regression model results obtained using KOA occurrence or progression as the objective variable and the number of MS components present as explanatory variables, after adjusting for age, gender, and the other potential risk factors listed in the Methods section, are shown in Fig. 3. The OR significantly increased with the number of MS components present after adjustment for



*:p < 0.05,***:p < 0.001

Multivariate logistic regression analysis using the occurrence or progression of KOA (over 3 years, 1: yes, 0: no) as the objective variable and the number of MS components as the explanatory variable, after adjusting for age, gender, region (0: coastal area, 1: mountainous area), smoking (0: ex- or non-smoker, 1: current smoker), alcohol consumption (0: ex- or non-drinker, 1: curre nt drinker), bicycling every day (0: no, 1: yes), regular exercise (0: no, 1: yes), and past history of knee injuries (0: no, 1: yes).

Fig. 3. ORs for occurrence and progression of KOA during the 3-year follow-up period vs the number of risk factors for MS.

other risk factors (OR, 95% CI vs no component: one component, 2.33, 0.96–5.65, $P = 0.065$; two components, 2.82, 1.05–7.54, $P = 0.039$; ≥three components, 9.83, 3.57–27.1, $P < 0.001$). Similarly, KOA progression significantly increased with the number of MS components present after adjustment for other risk factors (OR, 95% CI vs no component: one component, 1.38, 0.91–2.08, $P = 0.126$; two components, 2.29, 1.49–3.54, $P < 0.001$; ≥three components: 2.80, 1.68–4.68, $P < 0.001$). In both models, the OR for KOA occurrence significantly increased with the number of MS components present. Similar trends were observed for KOA progression with both models.

Discussion

In this study, we determined the cumulative incidence and progression rate of KOA diagnosed using the KL scale. We demonstrated that KOA occurrence and progression are associated with higher systolic BP, lower serum HDL-cho levels, and higher serum HbA1c levels, as well as higher BMI. Incorporating mutual adjustment for each MS component indicated that only BMI was significantly associated with KOA occurrence and progression. Regarding the risk factors for MS and KOA, even after adjusting for potential risk factors, multivariate analysis determined that HT and IGT were significantly associated with KOA occurrence, and OW and HT were significantly associated with KOA progression. The presence of a greater number of MS components was associated with a higher rate of KOA occurrence and progression. This tendency was much more pronounced in occurrence of KOA than in progression.

Numerous reports have presented an association between being OW or obese and KOA[1,7–12]. Lohmander *et al.* reported that being OW was associated with higher KOA incidence, and among measures of excess weight, BMI was observed to have the strongest relative risk gradient[28]. In the present study, we confirmed that BMI was the only continuous value significantly associated with KOA occurrence and progression among the MS risk factors (e.g., BMI, systolic BP, and serum levels of HDL-cho and HbA1c), consistent with previous studies. In contrast, several reports have shown that HT is associated with KOA presence, independent of OW[20,29–31]. In the present study, we confirmed a significant association between HT and IGT and KOA occurrence, and between OW and HT and KOA progression. Although several studies have found that obesity or increased BMI were risk factors for KOA onset[32–35], this appears to be the first report of associations between MS risk factors other than OW and KOA occurrence and progression.

There were differences between the results for continuous variables such as BMI, BP, and serum HDL-cho and HbA1c levels and those for categorical clinical criteria such as OW, HT, DL, and IGT. In analysis involving continuous variables, BMI was the only predictor of future KOA occurrence or progression. In contrast, clinical criteria-based analysis clearly showed associations between metabolic risk factors other than OW and KOA. This discrepancy suggests that the clinical criterion for OW (BMI ≥ 25 kg/m^2) may be less sensitive than continuous BMI values in reflecting the association of excess weight with KOA. We then performed additional analyses using KOA occurrence or progression as the objective variable and categorical risk factors for MS, such as HT, DL, and IGT, as explanatory variables. We also added continuous values for BMI at baseline rather than OW, after adjusting for multiple risk factors as listed for Model 2. The resulting overall ORs for HT, DL, and IGT adjusted for BMI on KOA occurrence or progression became smaller than those adjusted for OW. However, the association between HT and KOA occurrence remained significant (OR, 2.43; 95% CI, 1.14–5.18; $P = 0.021$), while IGT was no longer significant (OR, 1.70; 95% CI, 0.91–3.19; $P = 0.096$). Similarly, the association between HT and KOA progression remained significant (OR, 1.41; 95% CI, 1.00–2.00; $P = 0.049$). These results indicate that, even if associations between KOA and categorical MS components other than BMI are weak, if adjustments are made for OW using clinical criteria, then HT and IGT may be risk factors for KOA occurrence and HT may be a risk factor for KOA progression.

Regarding ethnic differences in KOA, we previously reported that KOA prevalence and incidence in the original ROAD study of 3,040 baseline participants was higher than those of Caucasians[36,37]. In contrast, with regard to ethnic differences in MS, Hoang *et al.* reviewed epidemiological studies and reported that MS prevalence in East Asians was lower than that in Caucasians[38]. MS prevalence in Asia may be increasing rapidly, as Nestel *et al.* reported a substantial increase in a cohort from Beijing from 9% in 1992 to 21% in 2002[39]. These ethnic differences have been suggested as resulting from genetic factors that modulate the association between KOA and obesity[40,41].

Regarding associations between risk factors of MS and KOA, Hart *et al.* attributed the effect of excess endogenous oestrogens to aromatization of oestrone in fat tissue[20]. Sowers *et al.* suggested that leptin and adiponectin levels influenced OA development[29]. Another hypothesis suggests that in obese subjects, metabolic changes in the striated muscles induced by interactions between insulin resistance and systemic inflammation may lead to fatigue and muscle weakness, influencing the balance between damage and repair mechanisms and ultimately leading to OA[42,43]. Inflammatory factors are suggested to be associated with both obesity and KOA[44,45]. Findlay evaluated the concept that vascular pathology might play a role in the initiation and/or progression of OA[46] and proposed that peripheral reduced blood flow associated with HT caused subchondral ischaemia. This ischaemia may in turn compromise nutrient and gas exchange into the articular cartilage and contribute to apoptosis of regional osteocytes of the subchondral bone. Furthermore, chondrocytes of OA exposed to high glucose concentrations exhibit impaired glucose transporter-1 downregulation[47]. Thus, impaired glucose transporter-1 downregulation may constitute an important pathogenic mechanism by which conditions characterized by hyperglycaemia may promote degenerative changes in chondrocytes, facilitating OA progression. However, in the present study, after adjustment for BMI, the effect of IGT was weak. Further studies are required to confirm whether IGT is a risk factor for KOA occurrence. Furthermore, because the present study aimed to identify associations between metabolic risk factors and future KOA occurrence or progression, we did not evaluate the effects of genetic factors and other risk factors potentially influencing MS and KOA. However, additional risk factors for both conditions should be addressed in further analysis of the ROAD study.

No previous studies have been performed on metabolic risk factor clustering and KOA occurrence or progression, although some cross-sectional epidemiological studies have evaluated the association between metabolic risk factor clustering and KOA presence[29,31]. In the present study, we demonstrated that KOA occurrence and progression are influenced not only by individual MS components but also by their clustering. An increase in the number of MS components significantly increases the risk of both KOA occurrence and progression. This effect of clustering was stronger for KOA occurrence than for KOA progression. Combining the present results with those of our previous report using the same analytical methods and adjustment factors[21], the ORs for ≥three components vs no components were 9.95, 2.79, and 2.72 for KOA occurrence, progression, and presence, respectively. Thus, preventing MS would aid in reducing every stage of KOA, including onset, worsening, and presence.

This study has several limitations. First, although it includes a relatively large number of participants, these participants do not

represent the entire general population because they were recruited from only two areas. Regarding potential selection bias of the ROAD study, we previously reported that no significant differences were identified between our participants and the general Japanese population, except that male participants aged 70–74 years in the ROAD study were significantly smaller in terms of body structure than the overall Japanese population ($P < 0.05$)[23]. Although we could locate and include baseline participants after 3 years with a high participation rate, this selection bias at baseline should be considered when generalising the results. Second, the definitions used for MS components were not completely identical to international criteria such as the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III, World Health Organization (WHO), or The American Association of Clinical Endocrinologists (AACE)[48]. As there has been considerable debate regarding abdominal circumference (≥85 cm in men, ≥90 cm in women) in the Japanese criteria[49], we decided to utilize BMI ≥ 25 kg/m^2 to indicate OW rather than abdominal circumference. Furthermore, because not all blood samples were obtained under fasting conditions, we did not use blood glucose and serum TG levels as indicators. Therefore, our results may underestimate the presence of MS components, especially DL and IGT. However, we used the alternative index for each condition, recommended by the National Health and Nutrition Survey for cases where collecting samples under fasting conditions is difficult[26], and thus our criteria likely reflect dysfunction in lipid and glucose metabolism. Finally, we used KL grade ≥ 2 for diagnosing KOA. However, the KL scale is a categorical index, and it is impossible to evaluate the minimum joint space and osteophytosis separately. To evaluate KOA severity using quantitative parameters, a KOA computer-assisted diagnostic system[50] measuring minimum joint space width and osteophytosis area is under development; this system will provide increased accuracy in determining the association between MS components and KOA development for early prevention of disability.

In conclusion, this study revealed that HT and IGT influence KOA occurrence and that OW and HT are associated with KOA progression. KOA occurred or worsened more frequently with increase in the number of MS components. Preventing MS may be useful in preventing both KOA occurrence and progression.

Author contributions

NY conceptualized the study, was primarily responsible for developing the protocol, and acts as the guarantor for this study. SM, HO, and TA conducted data collection and X-ray assessment. All authors reviewed the protocol and contributed to interpretation of the results. All authors were involved in drafting the article and approved the final version submitted for publication. All authors had full access to all of the data in the study and take responsibility for the integrity and accuracy of the data analyses.

Role of the funding source

This work was supported by Grants-in-Aid for Scientific Research B23390172 and B20390182 to NY, B23390357 and C20591737 to TA, B23390356 and C20591774 to SM, for Young Scientists A18689031 to HO, and Collaborating Research with NSF 08033011-00262 (Director, NY) from the Ministry of Education, Culture, Sports, Science, and Technology; and H17-Men-eki-009 (Director, KN), H18-Choujyu-037 (Director, TN), H20-Choujyu-009 (Director, NY), and H23-Chojyu-002 (Director, TA) from the Ministry of Health, Labour and Welfare in Japan. This study was also supported by grants from the Japan Osteoporosis Society (NY, SM, HO, and TA) and research aid from the Japanese Orthopaedic Association (JOA-Subsidized Science Project Research 2006-1 & 2010-2, Director, HK).

Conflict of interest

All authors declare that (1) no authors have received corporate support for the submitted work; (2) the authors have no relationships with companies that might have an interest in the submitted work in the previous 3 years; (3) the authors' spouses, partners, or children do not have financial relationships that may be relevant to the submitted work; and (4) the authors have no non-financial interests that may be relevant to the submitted work.

Acknowledgements

The authors wish to thank Dr Takako Nojiri and Mr Kazuhiro Hatanaka of the Gobo Public Health Centre; Dr Naoki Hirabayashi of the Kawakami Clinic, Hidakagawa Town; Mrs Tomoko Takijiri, Mrs Kumiko Shinou, Mrs Rie Takiguchi, Mrs Kyoko Maeda, Ms Ikuyo Ueyama, Mrs Michiko Mori, Mrs Hisayo Sugimoto, and other members of the public office in Hidakagawa Town; Dr Shinji Matsuda of the Shingu Public Health Centre; and Mrs Tamako Tsutsumi, Mrs Kanami Maeda, Mr Shoichi Shimoichi, Mrs Megumi Takino, Mrs Shuko Okada, Mrs Kazuyo Setoh, Mrs Chise Ryouno, Mrs Miki Shimosaki, Mrs Chika Yamaguchi, Mrs Yuki Shimoji, and other members of the public office in Taiji Town for their assistance in locating and scheduling participants for examinations. We also thank Ms Kyoko Yoshimura, Mrs Toki Sakurai, and Mrs Saeko Sahara for their assistance with data reduction and administration.

References

1. Sharma L, Kapoor D. Epidemiology of Osteoarthritis. Osteoarthritis: Diagnosis and Medical/Surgical Management. 4th edn. Philadelphia: Lippincott Williams & Wilkins; 2007.
2. Guccione AA, Felson DT, Anderson JJ, Anthony JM, Zhang Y, Wilson PW, *et al.* The effects of specific medical conditions on the functional limitations of elders in the Framingham study. Am J Public Health 1994;84:351–8.
3. Felson DT, Zhang Y. An update on the epidemiology of knee and hip osteoarthritis with a view to prevention. Arthritis Rheum 1998;41:1343–55.
4. Ministry of Health, Labour and Welfare. The Outline of the Results of National Livelihood Survey, http://www.mhlw.go.jp/toukei/list/20-19-1.html.
5. Dahlöf B. Cardiovascular disease risk factors: epidemiology and risk assessment. Am J Cardiol 2010;105:3A–9A.
6. Day C. Metabolic syndrome, or what you will: definitions and epidemiology. Diab Vasc Dis Res 2007;4:32–8.
7. Felson DT, Anderson JJ, Naimark A, Walker WM, Meenan RF. Obesity and knee osteoarthritis: the Framingham study. Ann Intern Med 1988;109:18–24.
8. Hart DJ, Spector TD. The relationship of obesity, fat distribution and osteoarthritis in the general population: the Chingford study. J Rheumatol 1993;20:331–5.
9. Van Saase JL, Vandenbroucke JP, Van Romunde LK, Valkenburg HA. Osteoarthritis and obesity in the general population. A relationship calling for an explanation. J Rheumatol 1998;15:1152–8.
10. Magliano M. Obesity and arthritis. Menopause Int 2008;14:149–54.
11. Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, *et al.* OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008;16:137–62.

12. Muraki S, Akune T, Oka H, Mabuchi A, En-yo Y, Yoshida M, *et al.* Association of occupational activity with radiographic knee osteoarthritis and lumbar spondylosis in elderly patients of population-based cohorts: a large-scale population-based study. Arthritis Rheum 2009;61:779–86.
13. Lawrence JS. Hypertension in relation to musculoskeletal disorders. Ann Rheum Dis 1975;34:451–6.
14. Kellgren JH. Osteoarthritis in patients and populations. BMJ 1961;1:1–6.
15. Cimmino MA, Cutolo M. Plasma glucose concentration in symptomatic osteoarthritis: a clinical and epidemiological survey. Clin Exp Rheumatol 1990;8:251–7.
16. Davis MA, Ettinger WH, Neuhaus JM. The role of metabolic factors and blood pressure in the association of obesity with osteoarthritis of the knee. J Rheumatol 1988;15:1827–32.
17. Cooper C, McAlindon T, Snow S, Vines K, Young P, Kirwan J, *et al.* Mechanical and constitutional risk factors for symptomatic knee osteoarthritis: differences between medial tibiofemoral and patellofemoral disease. J Rheumatol 1994;21:307–13.
18. Martin K, Lethbridge-Cejku M, Muller DC, Elahi D, Andres R, Tobin JD, *et al.* Metabolic correlates of obesity and radiographic features of knee osteoarthritis: data from the Baltimore Longitudinal Study of Aging. J Rheumatol 1997;24:702–7.
19. Stürmer T, Brenner H, Brenner RE, Günther KP. Non-insulin dependent diabetes mellitus (NIDDM) and patterns of osteoarthritis. The Ulm osteoarthritis study. Scand J Rheumatol 2001;30:169–71.
20. Hart DJ, Doyle DV, Spector TD. Association between metabolic factors and knee osteoarthritis in women: the Chingford study. J Rheumatol 1995;22:1118–23.
21. Yoshimura N, Muraki S, Oka H, Kawaguchi H, Nakamura K, Akune T. Association of knee osteoarthritis with the accumulation of metabolic risk factors such as overweight, hypertension, dyslipidaemia, and impaired glucose tolerance in Japanese men and women: the ROAD study. J Rheumatol 2011;38:921–30.
22. Yoshimura N, Muraki S, Oka H, Kawaguchi H, Nakamura K, Akune T. Cohort profile: Research on Osteoarthritis/Osteoporosis Against Disability (ROAD) study. Int J Epidemiol 2010;39:988–95.
23. Yoshimura N, Muraki S, Oka H, Mabuchi A, En-yo Y, Yoshida M, *et al.* Prevalence of knee osteoarthritis, lumbar spondylosis, and osteoporosis in Japanese men and women: the research on osteoarthritis/osteoporosis against disability study. J Bone Miner Metab 2009;27:620–8.
24. The Examination Committee of Criteria for Metabolic Syndrome. The definition and criteria of metabolic syndrome. Nihon Naika Gakkai zasshi 2005;94:794–809 (In Japanese).
25. Examination Committee of Criteria for Obesity Disease in Japan, Japan Society for the Study of Obesity. New criteria for 'obesity disease' in Japan. Circ J 2002;66:987–92.
26. Ministry of Health, Labour and Welfare. The Outline of the Results of National Health and Nutrition Survey, http://www.mhlw.go.jp/houdou/2009/11/dl/h1109-1b.pdf.
27. Kellgren JH, Lawrence JS. The Epidemiology of Chronic Rheumatism: Atlas of Standard Radiographs of Arthritis. Oxford: Blackwell Scientific; 1963.
28. Lohmander LS, Gerhardsson de Verdier M, Rollof J, Nilsson PM, Engstrom G. Incidence of severe knee and hip osteoarthritis in relation to different measures of body mass: a population-based prospective cohort study. Ann Rheum Dis 2009;68:490–6.
29. Sowers M, Karvonen-Gutierrez CA, Palmieri-Smith R, Jacobson JA, Jiang Y, Ashton-Miller JA. Knee osteoarthritis in obese women with cardiometabolic clustering. Arthritis Rheum 2009;61:1328–36.
30. Singh G, Miller JD, Lee FH, Pettitt D, Russell MW. Prevalence of cardiovascular disease risk factors among US adults with self-reported osteoarthritis: data from the Third National Health and Nutrition Examination Survey. Am J Manag Care 2002;8:S383–91.
31. Puenpatom RA, Victor TW. Increased prevalence of metabolic syndrome in individuals with osteoarthritis: an analysis of NHANES III data. Postgrad Med 2009;121:9–20.
32. Hart DJ, Doyle DV, Spector TD. Incidence and risk factors for radiographic knee osteoarthritis in middle-aged women: the Chingford study. Arthritis Rheum 1999;42:17–24.
33. Reijman M, Pols HA, Bergink AP, Hazes JM, Belo JN, Lievense AM, *et al.* Body mass index associated with onset and progression of osteoarthritis of the knee but not of the hip: the Rotterdam study. Ann Rheum Dis 2007;66:158–62.
34. Cooper C, Snow S, McAlindon TE, Kellingray S, Stuart B, Coggon D, *et al.* Risk factors for the incidence and progression of radiographic knee osteoarthritis. Arthritis Rheum 2000;43:995–1000.
35. Engström G, Gerhardsson de Verdier M, Rollof J, Nilsson PM, Lohmander LS. C-reactive protein, metabolic syndrome and incidence of severe hip and knee osteoarthritis. A population-based cohort study. Osteoarthritis Cartilage 2009;17:168–73.
36. Muraki S, Oka H, Akune T, Mabuchi A, En-yo Y, Yoshida M, *et al.* Prevalence of radiographic knee osteoarthritis and its association with knee pain in the elderly of Japanese population-based cohorts: the ROAD study. Osteoarthritis Cartilage 2009;17:1137–43.
37. Muraki S, Akune T, Oka H, Ishimoto Y, Nagata K, Yoshida M, *et al.* Incidence and risk factors for radiographic knee osteoarthritis and knee pain in Japanese men and women: a longitudinal population-based cohort study. Arthritis Rheum 2012;64:1447–56.
38. Hoang KC, Le TV, Wong ND. The metabolic syndrome in East Asians. J Cardiometab Syndr 2007;2:276–82.
39. Nestel P. Nutritional aspects in the causation and management of the metabolic syndrome. Endocrinol Metab Clin North Am 2004;33:483–92.
40. Manek NJ, Hart D, Spector TD, MacGregor AJ. The association of body mass index and osteoarthritis of the knee joint: an examination of genetic and environmental influences. Arthritis Rheum 2003;48:1024–9.
41. Qin J, Shi D, Dai J, Zhu L, Tsezou A, Jiang Q. Association of the leptin gene with knee osteoarthritis susceptibility in a Han Chinese population: a case-control study. J Hum Genet 2010;55:7046.
42. Kornaat PR, Sharma R, van der Geest RJ, Lamb HJ, Kloppenburg M, Hellio le Graverand MP, *et al.* Positive association between increased popliteal artery vessel wall thickness and generalized osteoarthritis: is OA also part of the metabolic syndrome? Skeletal Radiol 2009;38:1147–51.
43. Rojas-Rodríguez J, Escobar-Linares LE, Garcia-Carrasco M, Escárcega RO, Fuentes-Alexandro S, Zamora-Ustaran A. The relationship between the metabolic syndrome and energy-utilization deficit in the pathogenesis of obesity-induced osteoarthritis. Med Hypotheses 2007;69:860–8.
44. Pottie P, Presle N, Terlain B, Netter P, Mainard D, Berenbaum F. Obesity and osteoarthritis: more complex than predicted!. Ann Rheum Dis 2006;65:1403–5.
45. Goldring MB, Otero M. Inflammation in osteoarthritis. Curr Opin Rheumatol 2011;23:471–8.
46. Findlay DM. Vascular pathology and osteoarthritis. Rheumatology (Oxford) 2007;46:1763–8.
47. Rosa SC, Gonçalves J, Judas F, Mobasheri A, Lopes C, Mendes AF. Impaired glucose transporter-1 degradation and increased glucose transport and oxidative stress in response to

high glucose in chondrocytes from osteoarthritic versus normal human cartilage. Arthritis Res Ther 2009;11:R80.
48. Grundy SM, Brewer Jr HB, Cleeman JI, Smith Jr SC, Lenfant C, American Heart Association; National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433–8.
49. Shibata K, Suzuki S, Sato J, Ohsawa I, Goto S, Hashiguchi M, *et al.* Abdominal circumference should not be a required criterion for the diagnosis of metabolic syndrome. Environ Health Prev Med 2010;15:229–35.
50. Oka H, Muraki S, Akune T, Mabuchi A, Suzuki T, Yoshida H, *et al.* Fully automatic quantification of knee osteoarthritis severity on standard radiographs. Osteoarthritis Cartilage 2008;16:1300–6.

Does mild cognitive impairment affect the occurrence of radiographic knee osteoarthritis? A 3-year follow-up in the ROAD study

Noriko Yoshimura, Shigeyuki Muraki, Hiroyuki Oka, et al.

BMJ Open 2012 2:
doi: 10.1136/bmjopen-2012-001520